Analysis & Research
Data-driven investigations into Medicare Part D prescribing patterns.
The Medicare Opioid Crisis in Numbers
One in three Medicare prescribers write opioid prescriptions. We mapped the geographic and specialty hotspots.
Who Are the Highest-Cost Prescribers?
Some providers generate millions in drug costs. What drives the spending?
Brand vs Generic: The Billion-Dollar Gap
Generic drugs could save Medicare billions more. Which specialties resist the switch?
Geographic Hotspots for Opioid Prescribing
State-by-state analysis reveals persistent geographic patterns in opioid prescribing.
Excluded but Still Prescribing
We found 372 providers on the OIG exclusion list who appear in active Medicare prescribing data.
The Antipsychotic Problem in Elderly Care
Why CMS tracks antipsychotic prescribing to patients 65+ and what the data shows.
The $275 Billion Explosion: 5 Years of Medicare Drug Cost Growth
Medicare Part D drug costs surged 50% from $183B to $275.6B in five years. What's driving the explosion?
Which Medical Specialties Drive the Most Drug Spending?
From oncologists generating millions to primary care's aggregate impact — specialty prescribing patterns revealed.
Geographic Disparities in Medicare Prescribing
State-level spending and opioid variations reveal a 3x cost gap and persistent rural-urban divides.
The Drugs That Cost Medicare Billions
Eliquis: $7.75B. Ozempic: $4.3B. The top 20 drugs consume 22% of all Part D spending.
How We Score Prescribing Risk
Our 10-component model: specialty-adjusted z-scores, drug combination analysis, and OIG exclusion matching.
Where Does $275.6 Billion Go?
The big picture of Medicare Part D spending — who pays, where it flows, and policy implications.